What is the prognosis for patients with frontotemporal dementia and motor neuron disease? A new study suggests the answer depends not on which occurs first, but whether cognitive and motor symptoms develop simultaneously.
An analysis of 1274 patients with acute ischemic stroke (AIS) admitted to a single Colorado medical center over a 2-year period found that application of any acute stroke treatment strategy improved the patients’ NIH Stroke Scale (NIHSS) score.
Alzheimer disease (AD) is more than twice as likely to develop in elderly persons with orthostatic hypotension (OH) as in those without OH, according to a new study presented at the Annual Meeting of the American Academy of Neurology.
The total direct and indirect costs for treating patients with chronic migraines (CM) are 2.6 times higher than costs associated with episodic migraine (EM). Containing those costs through better management of the illness should be a priority, according to migraine researchers who led a nationwide study comparing the costs of CM and EM as part of the American Migraine Prevalence and Prevention (AMPP) Study.
The addition of methylprednisolone to interferon ß (IFN-ß) therapy may reduce disease activity in patients with multiple sclerosis (MS) to a greater degree than treatment with IFN-ß alone. “These results indicate that these 2 drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity,” said study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark.
New treatment options for pain caused by diabetic peripheral neuropathy were presented at the annual meeting of the American Academy of Neurology. While oral medications from 2 different drug classes appear effective, injection of botulinum toxin does not.
Elderly persons with essential tremor (ET) are almost twice as likely to have dementia as those without ET, according to a new study from Elan Louis, MD, professor of neurology, and colleagues at Columbia University in New York.
Thirteen years have passed since intravenous tissue plasminogen activator was approved for treating patients with acute ischemic stroke, but some experts think hospitals—even those designated as primary stroke centers—have been slow to implement the strategy.